Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Non-Current Liabilities (2020 - 2025)

Gain Therapeutics has reported Total Non-Current Liabilities over the past 6 years, most recently at $891648.0 for Q3 2025.

  • Quarterly results put Total Non-Current Liabilities at $891648.0 for Q3 2025, up 3.5% from a year ago — trailing twelve months through Sep 2025 was $891648.0 (up 3.5% YoY), and the annual figure for FY2024 was $872989.0, down 19.25%.
  • Total Non-Current Liabilities for Q3 2025 was $891648.0 at Gain Therapeutics, down from $940886.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for GANX hit a ceiling of $1.6 million in Q4 2021 and a floor of $815921.0 in Q1 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $1.1 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: increased 25.43% in 2021 and later plummeted 43.76% in 2024.
  • Gain Therapeutics' Total Non-Current Liabilities stood at $1.6 million in 2021, then plummeted by 32.22% to $1.1 million in 2022, then fell by 1.23% to $1.1 million in 2023, then decreased by 19.25% to $872989.0 in 2024, then grew by 2.14% to $891648.0 in 2025.
  • The last three reported values for Total Non-Current Liabilities were $891648.0 (Q3 2025), $940886.0 (Q2 2025), and $815921.0 (Q1 2025) per Business Quant data.